PPPraveen J. Patel

Praveen J. Patel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Praveen J. Patel has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Adnan Tufail

    From the National Institutes of Health Research (NIHR) Biomedical Research Centre for Ophthalmology (Moorfields Eye Hospital and UCL Institute of Ophthalmology), London, United Kingdom; and

    2 shared publications
  • Fred Kuanfu Chen

    Centre for Ophthalmology and Visual Science (Incorporating Lions Eye Institute), The University of Western Australia, Nedlands, Australia

    2 shared publications
  • Adnan Tufail

    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK

    1 shared publication
  • Catey Bunce

    Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK

    1 shared publication
  • Felicia Ikeji

    Moorfields Eye Hospital, London, UK

    1 shared publication
  • Gary S. Rubin

    From the National Institutes of Health Research (NIHR) Biomedical Research Centre for Ophthalmology (Moorfields Eye Hospital and UCL Institute of Ophthalmology), London, United Kingdom; and

    1 shared publication

Latest Publications

  • Test–Retest Variability of Reading Performance Metrics Using MNREAD in Patients with Age-Related Macular Degeneration

    by Praveen J. Patel, Fred K. Chen, Lyndon Da Cruz, Gary S. Rubin, Adnan Tufail

    Purpose. To determine the test–retest variability of reading ability using the MNREAD charts in patients with stable age-related macular degeneration (AMD). Methods. In this prospective study, reading ability was measured at two visits in 124 nontreated eyes of 124 patients with AMD, who were enrolled in an ongoing clinical trial using a standardized MNREAD protocol. Only patients with stable AMD who could perform the reading test at 40 cm at both visits were included in the analysis. Different scoring rules were applied to calculate critical print size and maximum reading speed. Results. Data from the 59 patients with a mean (SD) age of 78 (7.6) years who met the study criteria were analyzed at a mean (SD) interval of 43 (6) days between measurements. The 95% coefficient of repeatability (CR) was 0.30 logMAR for reading acuity. The CR for critical print size and maximum reading speed varied depending on the analysis method applied. Conclusions. This is a report of estimates of the intersession test–retest variability of reading performance metrics in patients with stable AMD. The results are helpful both in defining end points in clinical trials for AMD and in distinguishing clinical change from measurement variability in clinical practice.


  • Intersession repeatability of optical coherence tomography measures of retinal thickness in early age‐related macular degeneration

    by Praveen J. Patel, Fred K. Chen, Felicia Ikeji, Adnan Tufail

    : Purpose:  To determine the intersession repeatability of Stratus optical coherence tomography (OCT) measures of retinal thickness in patients with age‐related macular degeneration (AMD).Methods:  Measurement of retinal thickness was performed over four sessions over 12 weeks using a standardized OCT protocol with the fast macular thickness map in 67 non‐treated eyes of 67 patients with AMD enrolled in a clinical trial. The intrapatient standard deviation (Sw) and 95% coefficient of repeatability (CR) (), expressed in μm and as a percentage of mean retinal thickness, were calculated to estimate intersession repeatability.Results:  The CR was 32 μm for the average retinal thickness in the central 1 mm A1 subfield [95% confidence interval (CI) 31–33 μm] and 53 μm (95% CI 51–55 μm) for the centre‐point thickness (CPT). When expressed as a percentage, the CR was 15% (95% CI 14–16) for the central 1 mm A1 subfield and 29% (95% CI 27–30) for the CPT measure.Conclusion:  The average central 1 mm (A1) subfield retinal thickness measure shows good intersession repeatability in patients with stable, early AMD with poorer repeatability for the CPT measure. The results suggest that a change in Stratus OCT retinal thickness of more than 32 μm in the central A1 subfield is more indicative of true clinical change in these patients.


  • Open Access

    A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design

    by Praveen J Patel, Catey Bunce, Adnan Tufail, the ABC Trial Investigators

    Background: The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal injection which block the action of vascular endothelial growth factor-A (anti-VEGF agents). One such agent in widespread use is bevacizumab which was initially developed for use in oncology. Most of the evidence supporting the use of bevacizumab for nAMD has come from interventional case series and this clinical trial was initiated because of the increasing and widespread use of this agent in the treatment of nAMD (an off-label indication) despite a lack of definitive unbiased safety and efficacy data. Methods and design: The Avastin® (bevacizumab) for choroidal neovascularisation (ABC) trial is a double-masked randomised controlled trial comparing intravitreal bevacizumab injections to standard therapy in the treatment of nAMD. Patients are randomised to intravitreal bevacizumab or standard therapy available at the time of trial initiation (verteporfin photodynamic therapy, intravitreal pegaptanib or sham treatment). Ranibizumab treatment was not included in the control arm as it had not been licensed for use at the start of recruitment for this trial. The primary outcome is the proportion of patients gaining ≥ 15 letters of visual acuity at 1 year and secondary outcomes include the proportion of patients with stable vision and mean visual acuity change. Discussion: The ABC Trial is the first double-masked randomised control trial to investigate the efficacy and safety of intravitreal bevacizumab in the treatment of nAMD. This trial fully recruited in November 2007 and results should be available in early 2009. Important design issues for this clinical trial include (a) defining the control group (b) use of gain in vision as primary efficacy end-point and (c) use of pro re nata treatment using intravitreal bevacizumab rather than continuous therapy. Trial registration: Current controlled trials ISRCTN83325075